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Abstract
Aims: Transforming growth factor-b (TGF-b), fascin, nuclear factor-kappa B (NF-kB) p105, protein-kinase C-zeta (PKC-f),
partioning-defective protein-6 (Par-6), E-cadherin and vimentin are tumor promoting molecules through mechanisms
involved in cell dedifferentiation. In soft tissue sarcomas, their expression profile is poorly defined and their significance is
uncertain. We aimed to investigate the prognostic impact of TGF-b1, NF-kB p105, PKC-f, Par-6a, E-cadherin and vimentin in
non-gastrointestinal stromal tumor soft tissue sarcomas (non-GIST STSs).
Patients and Methods: Tumor samples and clinical data from 249 patients with non-GIST STS were obtained, and tissue
microarrays (TMAs) were constructed for each specimen. Immunohistochemistry (IHC) was used to evaluate marker
expression in tumor cells.
Results: In univariate analysis, the expression levels of TGF-b1 (P=0.016), fascin (P=0.006), NF-kB p105 (P=0.022) and PKC-
f, (P=0.042) were significant indicators for disease specific survival (DSS). In the multivariate analysis, high TGF-b1
expression was an independent negative prognostic factor for DSS (HR=1.6, 95% CI=1.1–2.4, P=0.019) in addition to
tumor depth, malignancy grade, metastasis at diagnosis, surgery and positive resection margins.
Conclusion: Expression of TGF-b1 was significantly associated with aggressive behavior and shorter DSS in non-GIST STSs.
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Introduction
Soft tissue sarcomas (STS) are malignant tumors arising from
extraskeletal connective tissues. They are group of heterogeneous
neoplasms, consisting of more than 50 subtypes, but comprise less
than 1% of adult malignancies [1,2]. Approximately 50% of the
STS patients will succumb to their disease because of metastasis or
local relapse [3]. The prognostic factors determining tumor
progression and ultimately patients’ fate include tumor grade,
size, location, depth, histological entity, positive resection margins
and presence of local recurrence [4–10]. Much attention is also
paid to recurrent gene aberrations in STSs as the predictive
biomarkers [11–13].
Molecular mechanisms regulating tissue changes from benign to
invasive and finally to metastatic neoplasia is an area of growing
scientific interest. Malignant transformation in epithelial tumors is
described as epithelial-to-mesenchymal transition (EMT). EMT is
defined as a sequence of protein modifications and transcriptional
events in response to a certain set of extracellular stimuli leading to
a stable, but sometimes reversible, cellular change [14].
Multiple molecular mediators of EMT have been described in
carcinomas [15]. The list of EMT pathways includes nuclear
factor-kappa B (NF-kB), AKT/mammalian target of rapamycin
(AKT/mTOR) axis, mitogen-activated protein kinase (MAPK),
beta-catenin, protein-kinase C (PKC) and others [16]. However,
expression of markers linked to EMT does not support EMT as a
biological event in STSs. Moreover, the markers linked to EMT
have clearly defined roles in tumor biology that are distinct from
EMT, and the negative impact of these factors on tumor behavior
can be rather defined as ‘‘defifferentiation’’ or ‘‘anaplasia’’ in these
tumors. The NF-kB and TGF-b pathways have been described to
influence the prognosis in several types of STS, including
malignant fibrous histiocytoma, Ewing sarcoma, osteosarcoma
and rhabdomyosarcoma [17–21]. Nevertheless, there are no
reports with emphasis on the prognostic value of E-cadherin,
fascin, Par-6 and PKC-f in STS. Vimentin, which is by definition
expressed by all STS, is a classic marker of higher aggressivity in
carcinoma. The intensity of vimentin expression can fluctuate, and
the significance of this variation for the STS patients’ survival is
not clear.
In this study, we investigate the expression of a panel of seven
molecular biomarkers in 249 non-GIST STS patients. We realize
that these tumors belong to different histological subtypes and
consequently have diverse prognoses. However, they all have
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17507mesenchymal derivation and belong therefore to the same generic
group, STS. The investigated dedifferentiation markers reflect
universal and basic processes in tumorigenesis, they are described
in a variety of epithelial and non-epithelial tumors of different
locations and histological entities and seem to not depend on
tumor type. This is confirmed by the fact that almost each of STS
type we investigated can show broad spectrum of malignancy
grade, from almost benign to high grade malignant tumor.
To our knowledge this is the first evaluation of such large
collection of dedifferentiation-associated biomarkers in non-GIST
STSs related to DSS.
Materials and Methods
Patients and clinical samples
Primary tumor tissue from anonymized patients diagnosed with
non-GIST STS at the University Hospital of Northern Norway
(UNN) 1973–2006 and The Hospitals of Arkhangelsk region,
Russia, were used in this retrospective study. In total, 496 patients
were registered from the hospital databases. Of these, 247 patients
were excluded due to missing clinical data (n=86) or inadequate
material for histological examination (n=161). Thus, 249 STS
patients with full clinical records and adequate paraffin-embedded
tissue blocks were eligible.
This report includes follow-up data as of September 2009. The
median follow-up was 38 months (range 0.1–392). Formalin-fixed
and paraffin-embedded tumor specimens were obtained from the
archives of the Departments of Pathology at UNN and the
Arkhangelsk hospitals. The tumors were graded according to the
French Fe `de `ration Nationales des Centres de Lutte Contre le
Cancer (FNCLCC) [22].
Microarray construction
All sarcomas were histologically reviewed by two trained
pathologists (S.S. and A.V.) and the most representative areas of
viable tumor cells (neoplastic cells) were carefully selected and
marked on the hematoxylin and eosin (H&E)-stained slides and
sampled for the tissue microarray blocks (TMAs). The TMAs were
assembled using a tissue-arraying instrument (Beecher Instru-
ments, Silver Springs, MD). The Detailed methodology has been
previously reported [23]. Briefly, we used a 0.6 mm diameter
stylet, and the study specimens were routinely sampled with two
replicate core samples (different areas) of neoplastic tissue. To
include all core samples, 12 tissue array blocks were constructed.
Multiple 4-mm sections were cut with a Micron microtome
(HM355S) and stained using specific antibodies for immunohis-
tochemistry (IHC) analyses.
Immunohistochemistry (IHC)
The applied antibodies were subjected to in-house validation by
the manufacturer for IHC analysis on paraffin-embedded material.
Fascin, 55K2; Cat.no. MAB3582 (mouse monoclonal; Chemicon
International; 1:25), NF-kB p105 (Ser933)178F3 Cat.no. 4808
(rabbit monoclonal; Cell Signaling Technology; 1:50), TGF-b1
(V):sc-146 (rabbit polyclonal; Santa Cruz; 1:50), PKC-f (C-20):sc-
216 (rabbit polyclonal; Santa Cruz; 1:100), Par-6a (H-90):sc-25525
(rabbit polyclonal; Santa Cruz; 1:10) E-cadherin (mouse monoclo-
nal; ECH-6; Cell Marque; prediluted), and vimentin (mouse
monoclonal; V9; Ventana Medical Systems; prediluted).
Sections (4 mM) were deparaffinized with xylene and rehydrated
with ethanol. Fascin and NF-kB were stained manually. Antigen
retrieval was performed exposing slides to microwave heating for
20 min at 450 W in 0.01M Citrate buffer pH 6.0. Primary
antibodies were incubated overnight in +4 degrees C (NF-kB), and
for 30 min at room temperature (fascin). Visualization reagents
were Vectastein ABC Elite-kit from Vector Laboratories (NF-kB)
and Envision+System-HRP (DAB) from DAKO (fascin).
TGF-b1, PKC-f, Par-6a, E-cadherin and vimentin were stained
using Ventana Benchmark XT (Ventana Medical Systems Inc),
procedure iViewDAB. Antigen retrieval was CC1 mild (TGF-b1,
PKC-f, Par-6a, E-Cadherin) and CC1 Standard (vimentin). For
E-cadherin post-fixative was selected. Primary antibodies against
TGF- b 1, PKC-f, E-cadherin and Par-6a were incubated at 37uC
for 28, 28, 32 and 52 min, accordingly. As secondary antibodies
biotinylated goat anti-mouse IgG and mouse anti-rabbit IgM were
used. This was followed by application of liquid diaminobenzidine
as substrate-chromogen, yielding a brown reaction product at the
site of the target antigen (iView DABH procedure). Finally, slides
were counterstained with hematoxylin to visualize the nuclei. For
each antibody, including negative controls, all TMA staining were
performed in a single experiment.
Scoring of IHC
The ARIOL imaging system (Genetix, San Jose, CA) was used
to scan the slides with immunohistochemically stained TMAs. The
specimens were scanned at a low resolution (1.256) and high
resolution (206) using Olympus BX 61 microscope with an
automated platform (Prior). The slides were loaded in the
automated slide loader (Applied Imaging SL 50). Representative
and viable tissue sections were scored manually on computer
screen, semiquantitatively for cytoplasmic staining. The dominant
staining intensity in neoplastic cells was scored subjectively as:
0=negative; 1=weak; 2=intermediate; 3=strong (Figure 1). All
samples were anonymized and independently scored by two
pathologists (A.V. and S.S.). In cases where score difference was
equal or exceeding 2, the slides were re-examined and a consensus
was reached by the observers. When assessing a score for a given
core, the observers were blinded to the scores of the other variables
and to outcome. Mean score for duplicate cores from each
individual was calculated.
Statistical methods
All statistical analyses were done using the statistical package
SPSS (Chicago, IL), version 16. The IHC scores from each
observer were compared for interobserver reliability by use of a
two-way random effect model with absolute agreement definition.
The intraclass correlation coefficient (reliability coefficient) was
obtained from these results. The Chi-square test and Fishers Exact
test were used to examine the association between molecular
marker expression and various clinicopathological parameters.
Univariate analyses were done by using the Kaplan-Meier
method, and statistical significance between survival curves was
assessed by the log rank test. Disease-specific survival (DSS) was
determined from the date of histological confirmed STS diagnosis
to the time of STS death. To assess the independent value of
different pretreatment variables on survival, in the presence of
other variables, multivariate analysis was performed using the Cox
proportional hazards model. Only variables of significant value
from the univariate analysis were entered into the Cox regression
analysis. Probability for stepwise entry and removal was set at 0.05
and 0.10, respectively. The significance level used in both
univariate multivariate analyses was P,0.05, but in the post hoc
subgroup analysis the significance level was moved from P=0.05
to P=0.01 due to risk of false positivity.
Ethical clearance
The National Cancer Data Inspection Board and The Regional
Committee for Research Ethics approved the study. The Regional
Dedifferentiation Markers in Sarcomas
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their information to be stored in the hospital database and used for
research was not needed because most of the material was more
than 20 years old and most of the patients are now dead. The
material was collected from our approved biobank for paraffin-
embedded material and slides. All material was anonymously
collected. The data were analyzed anonymously.
Results
Clinicopathological variables
The clinicopathological variables are summarized in Table 1.
Median age was 59 (range, 0–91) years and 56% were female.
The non-GIST STS comprised 249 tumors including pleomor-
phic sarcoma (n=68), leiomyosarcoma (n=67), liposarcoma
(n=34), fibrosarcoma (n=20), rhabdomyosarcoma (n=16),
synovial sarcoma (n=16), angiosarcoma (n=13), malignant
peripheral nerve sheath tumor (MPNST) (n=11) and other
types of sarcoma (n=4). The tumors were localized in the
extremities (n=89), trunk (n=47), retroperitoneum (n=37),
head/neck (n=18) and viscera (n=58). The treatment option
of choice was surgery (n=228), 120 patients received surgery
alone, 55 patients received surgery and radiotherapy, 40 patients
received surgery and chemotherapy, 13 patients received surgery,
radiotherapy and chemotherapy. Of the non-operated patients
(inoperable, n=11; advanced age/other serious disease, n=5,
STS diagnosis confirmed post mortem, n=3; patient refusal,
n=2) seven received chemotherapy and/or radiotherapy.
Fourteen patients did not obtain any treatment.
Interobserver variability
Interobserver scoring agreement was tested for all markers. The
intraclass correlation coefficients were as follows: 0.92 for E-
cadherin (P,0.001), 0.89 for fascin (P,0.001), 0.91 for NF-kB
p105 (P,0.001), 0.86 for Par-6a (P,0.001), 0.97 for PKC-f
(P,0.001), 0.87 for TGF-b1( P ,0.001) and 0.93 for vimentin
(P,0.001).
Expression pattern and correlations with
clinicopathological variables
The TGF-b1, NF-kB p105, fascin, Par-6a, PKC-f and
vimentin, showed expression in the cytoplasm of tumor cells while
E-cadherin demonstrated focal membrane-associated and/or
cytoplasmic positivity in a minority of the tumors.
TGF-b1, fascin and Par-6a expression significantly correlated
with STS histological grade. Low-grade tumors expressed TGF-b1
in 20% of cases, while high-grade tumors did so in 42%
(P=0.008). For fascin, this low- to high grade ratio of marker
expression comprised 15% to 52% (P,0.001). PKC-f, Par-6a and
NF-kB p105 positivity in STSs correlated with their subsequent
metastatic behavior. PKC-f expression was observed in 36% of
metastasizing tumors, whereas only 22% non-metastasizing STSs
(P=0.016) were PKC-f positive. For Par-6a this metastasizing
versus non-metastasizing characteristic comprised 72% and 56%
Figure 1. IHC analysis of TMA of non-GIST STS representing different scores of expression of dedifferentiation related markers in
tumor cells. A, Leiomyosarcoma, histological grade I, E-cadherin, negative staining, score 0; B, Dedifferentiated liposarcoma, histological grade II,
TGF-b1, weak staining, score 1; C, Pleomorphic liposarcoma, histological grade III, Fascin, moderate staining; score 2; D, Alveolar rhabdomyosarcoma,
histological grade III, Vimentin, strong staining, score 3. All calibration bars correspond to 100 mm. Abbreviations; IHC, immunohistochemistry; TMA,
tissue microarray; non-GIST STS, non gastro-intestinal stromal tumor soft-tissue sarcoma; TGF-b1, transforming growth factor beta 1.
doi:10.1371/journal.pone.0017507.g001
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Characteristic
Patients
(n)
Patients
(%)
Median survival
(months)
5-Year survival
(%) P
Age
# 20 years 20 8 15 40 0.126
21–60 years 113 45 68 52
.60 years 116 47 30 40
Gender
Male 110 44 41 46 0.390
Female 139 56 45 45
Patient nationality
Norwegian 167 67 63 51 0.011
Russian 82 33 22 34
Histological entity
Pleomorphic sarcoma 68 27 29 40 0.102
Leiomyosarcoma 67 27 45 46
Liposarcoma 34 14 NR 67
MF/MFT 20 8 43 50
Angiosarcoma 13 5 10 31
Rhabdomyosarcoma 16 6 17 38
MPNST 11 5 49 45
Synovial sarcoma 16 6 31 29
Other STSs 4 2 NR 18
Tumor localization
Extremities 89 36 100 53 0.348
Trunk 47 29 32 44
Retroperitoneum 37 25 25 38
Head/Neck 18 7 15 41
Visceral 58 23 30 42
Tumor size
# 5 cm 74 30 127 57 0.027
5–10 cm 91 37 44 45
.10 cm 81 32 28 36
Missing 3 1
Malignancy grade
16 1 2 5 N R 7 4 ,0.001
29 8 3 9 4 1 4 5
39 0 3 6 1 6 2 6
Tumor depth
Superficial 17 7 NR 93 ,0.001
Deep 232 93 36 42
Metastasis at time of diagnosis
No 206 83 76 53 ,0.001
Yes 43 17 10 10
Surgery
Yes 228 92 59 50 ,0.001
No 21 8 5 0
Resection margins
Free 178 71 127 66 ,0.001
Not free/no surgery 71 29 10 18
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respectively. None of the investigated markers correlated signifi-
cantly with age, gender, tumor location, depth, size or relapse rate.
Univariate analyses
Data are presented in Table 1. Patient nationality (P=0.011),
tumor size (P=0.027), malignancy grade (P,0.001), tumor depth
(P,0.001), metastasis at time of diagnosis (P,0.001), surgery
(P,0.001) and resection margins (P,0.001) were all significant
prognostic variables for DSS.
The prognostic impact on DSS by the investigated molecular
factors is shown in Table 2. Among these, TGF-b1 (P=0.016),
fascin (P=0.006), NF-kB p105 (P=0.022) and PKC-f (P=0.042)
were significant indicators of shorter DSS. Disease-specific survival
curves for these markers are correspondingly shown in Figure 2,
A–D.
Stratification of cases based on clinical variables revealed that
high TGF-b1 expression was a negative prognostic indicator
particularly for pleomorphic sarcoma (P,0.001) and for trunk-
located STS (P=0.003).
Multivariate Cox proportional hazards analyses
Only variables which were significant in univariate analyses
were entered into the multivariate analysis. The results of the
multivariate analysis are presented in Table 3. Tumor depth
(P=0.017), histological entity (P=0.027), malignancy grade
(P,0.001), metastasis at time of diagnosis (P=0.011), surgery
(P=0.002), non-free resection margins (P,0.001), and TGF-b1
expression (P=0.035) were significant independent prognostic
indicators of DSS.
Discussion
In our large-scale retrospective study we sought to investigate
the prognostic impact of a set of biomarkers in non-GIST STS
patients. These markers are known to participate in the process of
EMT in epithelial tumors [14], but bear other important
biological functions as well. Moreover, the EMT concept has
not received general acceptance [24]. STSs are of mesenchymal
origin and can demonstrate a range of behavior patterns, varying
from almost benign to highly aggressive tumors. TGF-b1, fascin,
NF-kB p 105 and PKC-f showed significant unfavorable
influence on survival in the univariate analyses. Besides, high
expression of TGF-b1 was a significant independent negative
prognostic indicator of DSS. To our knowledge this is the first
prognostic evaluation of these biomarkers in whole-array non-
GIST STSs.
Characteristic
Patients
(n)
Patients
(%)
Median survival
(months)
5-Year survival
(%) P
Chemotherapy
No 191 77 52 47 0.424
Yes 58 23 29 40
Radiotherapy
No 176 71 48 46 0.590
Yes 73 29 38 43
Abbreviations: NR, not reached; MF/MFT, malignant fibroblastic/myofibroblastic tumors; MPNST, malignant peripheral nerve sheath tumor; NOS, not otherwise
specified; non-GIST STS, non-gastro intestinal stromal tumor soft-tissue sarcoma.
doi:10.1371/journal.pone.0017507.t001
Cont 1.
Table 2. Tumor expression of markers associated with
dedifferentiation and their prognostic impact on disease-
specific survival in patients with non-GIST STSs (univariate
analyses; log-rank test, n=249).
Marker
expression
Patients
(n)
Patients
(%)
Median
survival
(months)
5-Year
survival
(%) P
TGF-b1
Low 170 68 62 66 0.016
High 74 30 25 31
Missing 5 2
E-cadherin
Negative 193 77 58 71 0.659
Positive 39 16 48 39
Missing 17 7
Fascin
Low 153 61 80 53 0.006
High 91 37 17 36
Missing 5 2
NF-kB p105
Negative 59 24 NR 60 0.022
Positive 184 74 37 41
Missing 6 2
Par-6a
Low 91 37 62 50 0.283
High 153 61 38 44
Missing 5 2
PKC-f
Negative 174 70 57 49 0.042
Positive 66 27 27 37
Missing 9 3
Vimentin
Low 83 34 48 46 0.616
High 157 63 41 45
Missing 9 3
Abbreviations: Non-GIST STS, non-gastro intestinal stromal tumor soft-tissue
sarcoma; TGF-b1, transforming growth factor beta 1; NF-kB, nuclear factor-kB; Par-
6a,partitioning-defectiveprotein6a;PKC-f,proteinkinaseCzeta;NR,not reached.
doi:10.1371/journal.pone.0017507.t002
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in order to end proliferation, induce differentiation, or promote
apoptosis in normal cells, thus being a natural tumor-suppressive
agent. Though in tumorigenesis this mediator initiates EMT
through activation of Smad and non-Smad signalling pathways
[25]. Such pro-neoplastic action becomes possible through either
blockade of the TGF-b pathway with receptor-inactivating
mutations, or selective inactivation of the tumor-inhibiting arm
of this pathway [26]. Another possibility is TGF-b induced
systemic immune suppression [27]. The TGF-b pathway activa-
tion has been shown to negatively influence prognosis both in
epithelial [28,29] and in mesenchymal bone [30] and soft tissue
tumors [18,21,31]. The latter studies, however, are devoted to one
particular STS type, while investigations of TGF-b1 expression by
whole-array human STS with concern to impact on survival are
not reported. In the present study, TGF-b1 was found to be a
crucial prognostic marker. It had an independent significantly
negative prognostic effect on DSS in non-GIST STS.
TGF-b was called the Jekyl and Hyde of cancer [32] for its
ability to modulate its action from tumor promoter to tumor
suppressor. The factors responsible for such transition remain
unclear. The candidates are both tumour-cell-autonomous TGF-b
signalling [33] itself, and factors in the tumor microenvironment.
Among the latter, inflammatory cells and cancer-associated
fibroblasts [27], as well as angiogenetic factors [33], are considered
the most potent modulators of TGF-b action. In previous studies,
we have investigated the prognostic value of both inflammatory
cells [34] and angiogenetic factors in STSs [35], and further plan
to explore their interactions with TGF-b.
Fascin and E-cadherin are both related to cell motility and cell
adhesiveness and important factors in the progression
and metastasis of cancers [36]. Fascin is reported to be
overexpressed in sarcomatoid, in contrast to conventional, non-
small cell lung carcinoma [37]. In leiomyomatous tumors of the
uterus it was associated with higher malignancy grade [38]. We
found fascin expression to be associated with a shorter STS survival
in univariate analyses, but not in multivariate. E-cadherin, being
responsible for epithelial cell junction, is rarely expressed in STS,
except for synovial and epithelioid sarcomas, as well as mesothe-
lioma, which naturally express both epithelial and mesenchymal
markers. As could be expected, E-cadherin was in this study
expressed aberrantly in a minority of STS and failed to demonstrate
any association with survival.
NF-kB 1 (p50 and its precursor p105) is one of five members of
the NF-kB family. These are transcription proteins responsible for
control of inflammation, regulation of cell cycle and cell
proliferation. NF-kB is constitutively activated in various tumor
cells where it promotes cell proliferation, survival, metastasis,
inflammation, invasion, and angiogenesis [39]. Its influence on
tumorigenesis is rather controversial. Indeed, while the majority of
the investigators confirm that this marker augments tumor
invasiveness and metastasis resulting in shorter DSS, in a recent
study by Al-Saad et al., NF-kB p 105 was reported to have a
favourable impact on DSS in operable non-small cell lung
Figure 2. Disease-specific survival curves for dedifferentiation-associated markers. A, TGF-b1; B, Fascin; C, NF-kB p105; D, PKC-f.
Abbreviations: TGF-b1, transforming growth factor beta 1; NF-kB, nuclear factor-kB; PKC-f, protein kinase C zeta.
doi:10.1371/journal.pone.0017507.g002
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to indicate a poor prognosis.
Par-6 and PKC-f (one of four atypical PKCs) belong to the
Par3/Par-6/aPKC polarity complex that governs diverse cell
functions such as localization of embryonic determinants and
establishment of tissue and organ during the embryonal period
and regulation of cell polarity and the asymmetric division of cells
in mature organisms [41]. Both Par-6 and PKC-f have been
identified as EMT-associated biomarkers [42] and found to
enhance proliferation, migration and invasiveness in cell cultures
[43,44]. We were unable to retrieve studies on Par-6 expression in
human tumor tissue through PubMed searches. Cornford et al.
reported that PKC-f expression was significantly higher in
prostatic carcinomas than in non-neoplastic prostate tissue [45].
In STS, we observed that PKC-f expression was a significant
indicator of shorter DSS.
Vimentin is an acknowledged marker of higher aggressivity in
epithelial tumors. Its negative influence on patient survival has
been demonstrated in several human cancers including breast
[46], gastric [47] and oral squamous cell carcinoma [48]. The
STSs which by definition express vimentin are not generally
investigated for the prognostic importance of its grade of
expression. In our material, all tumor cells were positive for
vimentin, but at varying degrees. All STSs were dichotomized as
strongly positive tumors or not, but there was no difference in
survival between these two groups of patients.
In conclusion, we have characterized the STS phenotype with
respect to tumor aggressiveness and DSS. We found also that all
the tumors included in the non-GIST STS group shared this
phenotype at different degrees. Moreover, our findings are in
agreement with results of a number of studies that have
investigated the roles of these markers in other, especially
epithelial, tumors. This makes us to believe that the processes
we have explored in the study are universal and are not a feature
of one or several distinct entities.
Although the precise molecular interactions resulting in STS
tumor cell dedifferentiation are still unclear, our findings may help
to identify a subgroup of patients with aggressive tumors which
require adjuvant therapy. Moreover, the biomarkers indicating
such aggressiveness can represent molecular targets with the future
development of small-molecule targeted therapy.
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